Threefold Higher Risk for Breast Cancer Death With DCIS Threefold Higher Risk for Breast Cancer Death With DCIS
Compared to the general population, women with ductal carcinoma in situ (DCIS) were more than three times more likely to die from breast cancer; the risk was particularly high for Black women and young women.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 18, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Women with DCIS have 3x the risk of breast cancer death
A new study adds weight to the belief that ductal carcinoma in situ (DCIS)...Read more on AuntMinnie.comRelated Reading: Delayed breast cancer surgery not tied to worse outcomes Preop MRI finds 11% more cancer in women with DCIS Years later, DCIS tied to more imaging but not anxiety Black women still at higher risk of breast cancer death Does imaging modality influence DCIS recurrence? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 17, 2020 Category: Radiology Source Type: news

Surgical Delays Not Life-Threatening in Early Breast Cancer
WEDNESDAY, Aug. 12, 2020 -- Surgical delays do not seem to be life-threatening for women with ductal carcinoma in situ (DCIS) or with early-stage estrogen receptor-positive (ER+) breast cancer, according to a study published online Aug. 6 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 12, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoi...
Source: Roche Media News - August 6, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoi...
Source: Roche Investor Update - August 6, 2020 Category: Pharmaceuticals Source Type: news

Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory t...
Source: Roche Media News - August 3, 2020 Category: Pharmaceuticals Source Type: news

Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory t...
Source: Roche Investor Update - August 3, 2020 Category: Pharmaceuticals Source Type: news

Oncotarget: The Golgi protein TMEM165 controls migration/invasion for carcinoma
(Impact Journals LLC) The cover for issue 28 of Oncotarget features Figure 5, 'TMEM165 expression levels alters N-linked glycosylation,' by Murali, et al., and reported that the TMEM165 protein was not detected in non-malignant matched breast tissues and was detected in invasive ductal breast carcinoma tissues by mass spectrometry. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 14, 2020 Category: International Medicine & Public Health Source Type: news

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers a...
Source: Roche Media News - July 13, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers a...
Source: Roche Investor Update - July 13, 2020 Category: Pharmaceuticals Source Type: news

New compounds from starfish of Kuril basin show efficacy against cancer cells.
(Far Eastern Federal University) Russian scientists from Far Eastern Federal University (FEFU), G. B. Elyakov Pacific Institute of Bioorganic Chemistry (PIBOC FEB RAS), and A.V. Zhirmunsky National Scientific Center for Marine Biology (NSCMB FEB RAS) have discovered four new steroid substances which target cells of human breast cancer, and colorectal carcinoma. They were extracted from the starfish Ceramaster patagonicus, a Kuril basin seabed dweller. A related article appears in Marine Drugs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 26, 2020 Category: Cancer & Oncology Source Type: news

Preop MRI finds 11% more cancer in women with DCIS
Preoperative breast MRI finds 11% more cancer in women with ductal carcinoma...Read more on AuntMinnie.comRelated Reading: Years later, DCIS tied to more imaging but not anxiety Who gets breast cancer treatment during a pandemic? Breast MRI works as presurgical tool 10-minute breast MRI scan beats DBT for invasive cancer Does imaging modality influence DCIS recurrence? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 24, 2020 Category: Radiology Source Type: news

Roche ’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer
Basel, 18 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion031 study, evaluating Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel; followed by doxorubicin and cyclophosphamide) in comparison to placebo plus chem otherapy (including Abraxane), met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in pathological complete response (pCR) for the treatment of people with early triple-negative breast cancer (TNBC), regardless of PD-L1 expression.“Tripl...
Source: Roche Media News - June 18, 2020 Category: Pharmaceuticals Source Type: news

Increased Risk for Invasive Breast Cancer After DCIS Increased Risk for Invasive Breast Cancer After DCIS
A new analysis shows that any diagnosis of ductal carcinoma in situ is associated with a long-term risk of invasive breast cancer and that treatment lowers this risk.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 5, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA approves Roche ’s Tecentriq in combination with Avastin for people with the most common form of liver cancer
Basel, 2 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received p rior systemic therapy.“We’re excited that today’s approval of Tecentriq in combination with Avastin for unresectable or metastatic hepatocellular carcinoma brings a cancer immunotherapy option to people with this aggressive form of liver cancer,” said Levi Garraway, M.D., Ph....
Source: Roche Media News - June 2, 2020 Category: Pharmaceuticals Source Type: news

Very Early-Stage Breast Cancer Ups Long-Term Odds for Invasive Tumors: Study
FRIDAY, May 29, 2020 -- Women with cancerous cells in their milk ducts -- also known as DCIS -- are at a high risk for developing fatal breast cancer, British researchers report. DCIS is short for ductal carcinoma in situ, an early form of breast... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 29, 2020 Category: General Medicine Source Type: news

Trastuzumab achieves slight reduction in recurrence for women with HER2-positive DCIS
(NRG Oncology) The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) on the NRG Oncology clinical trial NSABP B-43. The trial did find a statistically non-significant, modest (19%) reduction in the rate of recurrence among women that received trastuzumab, but this difference was not statistically significant. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 29, 2020 Category: Cancer & Oncology Source Type: news

Risk for Later Invasive Breast Cancer Up for Women With DCIS
THURSDAY, May 28, 2020 -- Women with screening-detected ductal carcinoma in situ (DCIS) have increased long-term risks for invasive breast cancer and breast cancer death, according to a study published online May 27 in The BMJ. Gurdeep S. Mannu,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 28, 2020 Category: Pharmaceuticals Source Type: news

Years later, DCIS tied to more imaging but not anxiety
In the five years after treatment, women with a history of ductal carcinoma...Read more on AuntMinnie.comRelated Reading: Who gets breast cancer treatment during a pandemic? Sentinel lymph node biopsy unnecessary for DCIS Does imaging modality influence DCIS recurrence? Preop breast MRI improves DCIS surgical planning (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 26, 2020 Category: Radiology Source Type: news

How to Think About Your Cancer Care in the Time of COVID-19
Getting the news that you have cancer is overwhelming and frightening. The COVID-19 crisis adds another layer of anxiety. But know this: you can protect yourself from COVID-19 without compromising your cancer treatment. Don’t panic. In the vast majority of cases, a diagnosis of cancer is not an emergency even though it feels like one. There is time to learn about your options and sort out what is right for you. For now, there will be changes to how we do things. Some of the changes will feel disruptive, but many will lead to better, more patient-centered care. Minimizing your chances of exposure to the virus doesn&rs...
Source: TIME: Health - April 28, 2020 Category: Consumer Health News Authors: Dr. Laura Esserman Tags: Uncategorized COVID-19 Source Type: news

Sporadic activation of an oxidative stress-dependent NRF2-p53 signaling network in breast epithelial spheroids and premalignancies
Breast and mammary epithelial cells experience different local environments during tissue development and tumorigenesis. Microenvironmental heterogeneity gives rise to distinct cell regulatory states whose identity and importance are just beginning to be appreciated. Cellular states diversify when clonal three-dimensional (3D) spheroids are cultured in basement membrane, and one such state is associated with stress tolerance and poor response to anticancer therapeutics. Here, we found that this state was jointly coordinated by the NRF2 and p53 pathways, which were costabilized by spontaneous oxidative stress within 3D cult...
Source: Signal Transduction Knowledge Environment - April 14, 2020 Category: Science Authors: Pereira, E. J., Burns, J. S., Lee, C. Y., Marohl, T., Calderon, D., Wang, L., Atkins, K. A., Wang, C.-C., Janes, K. A. Tags: STKE Research Articles Source Type: news

Breast Cancer Survivor Advises Getting Mammograms Once Coronavirus Threat Ends
BOSTON (CBS) — Julie Tolek remembers the exact minute her life changed forever: June 26, 2019. It was eight in the morning when she was diagnosed with breast cancer. “I thought I was in a dream. Nightmare, I guess, is a better description,” Tolek recalled. “I couldn’t say the word. It couldn’t be my life.” The diagnosis: stage two grade two invasive ductal carcinoma — an aggressively growing cancer. “I chose to have a double mastectomy even though my cancer was only in one breast. I decided I wanted to do everything in my power to not have to go through this again,&rdqu...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - April 3, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Syndicated Local Breast Cancer Coronavirus Juli McDonald Mammograms Source Type: news

PreludeDx Announces New Response Type Biosignature Data at the 37th Annual Miami Breast Cancer Conference
New Response Type™ Biosignature Identifies Women at Elevated Risk of Recurrence after Surgery and Radiation Therapy for DCIS DCISionRT integration into decision-making changed treatment recommendations in 45% of women with DCIS Prospective Trial near... Diagnostics, Oncology PreludeDx, DCISionRT, ductal carcinoma, breast cancer, DCIS (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 6, 2020 Category: Pharmaceuticals Source Type: news

Neoadjuvant Imatinib for an Uncommon Breast Malignancy Neoadjuvant Imatinib for an Uncommon Breast Malignancy
This case highlights the differentiation of dermatofibrosarcoma protuberans from metaplastic breast carcinoma and other spindle cell lesions, as well as the use of imatinib as neoadjuvant treatment.Journal of Medical Case Reports (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 18, 2020 Category: Surgery Tags: Family Medicine/Primary Care Journal Article Source Type: news

China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy...
Source: Roche Media News - February 14, 2020 Category: Pharmaceuticals Source Type: news

China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy...
Source: Roche Investor Update - February 14, 2020 Category: Pharmaceuticals Source Type: news

Roche to present new data on Tecentriq in combination with Avastin that shows improvement in overall survival for Chinese patients with the most common form of liver cancer
Basel, 7 February 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that additional data will be presented from a cohort of Chinese patients in the Phase III IMbrave150 study that evaluated Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. Data from 194 Chinese patients who took part in the IMbrave150 study were consistent with the global results, that showed a statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free...
Source: Roche Investor Update - February 7, 2020 Category: Pharmaceuticals Source Type: news

Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer
      ·Application is being reviewed under FDA ’s Real-Time Oncology Review pilot programmeBasel, 27 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), for the treatment of people with unresectab le hepatocellular carcinoma (HCC) who have not received prior systemic therapy. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, wh...
Source: Roche Investor Update - January 27, 2020 Category: Pharmaceuticals Source Type: news

RT for DCIS Ups Mortality Risk in Invasive Second Breast Cancer
FRIDAY, Dec. 20, 2019 -- For women with primary ductal carcinoma in situ (DCIS), use of radiotherapy (RT) is associated with increased rates of breast cancer-specific mortality for those women who subsequently develop an invasive second breast... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 20, 2019 Category: Pharmaceuticals Source Type: news

Patients with Invasive Secondary Breast Cancer May Have Higher Mortality
Patients who previously received radiotherapy for ductal carcinoma in situ may have higher mortality after developing an invasive second breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 3, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

New Study Suggests Women With Dense Breast Tissue May Benefit From Regular MRIs
While there has been some controversy over when women should start getting mammograms, all experts agree that screening is an important first step in detecting breast cancers and treating them early. But for some women, that’s not enough. For the approximately 40% of women with dense breast tissue, and especially the 10% with extremely dense tissue, cancer cells are harder to detect, since the denser tissue can mask small growths. In addition, dense breast tissue itself is also a risk factor for developing cancer. There’s been debate among experts over whether these women should have additional screening, on to...
Source: TIME: Health - November 27, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Breast Cancer embargoed study Research Source Type: news

Mesothelioma Death from 9/11 Signals Start of Things to Come
Malignant mesothelioma has become the latest deadly cancer linked directly to the rescue, recovery and cleanup efforts following the 9/11 terrorist attack on New York City in 2001. The long-running threat has come to fruition. Eighteen years after Manhattan was engulfed in the asbestos-laced, toxic cloud of dust — caused primarily by the World Trade Center destruction — the first death from pleural mesothelioma attributed to 9/11 has been recorded. Nick Ursta, 52, from the southwestern part of Pennsylvania, died after a year-long battle with the rare cancer. Ursta, a construction worker and fireman by trade, w...
Source: Asbestos and Mesothelioma News - November 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Palbociclib With Endocrine Therapy for HR+ Breast Carcinoma Palbociclib With Endocrine Therapy for HR+ Breast Carcinoma
In a new study, patients with HR+/HER2- early stage breast cancer completed 2 years of adjuvant palbociclib with a similar toxicity profile as that observed in the metastatic setting.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 13, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

No Benefit Seen for SLNB in BCS for DCIS in Older Women
THURSDAY, Oct. 31, 2019 -- For older patients with ductal carcinoma in situ (DCIS) who undergo breast-conserving surgery (BCS), sentinel lymph node biopsy (SLNB) is not associated with improvements in long-term outcomes, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 31, 2019 Category: Pharmaceuticals Source Type: news

Don't Delay Very Early-Stage Breast Cancer Surgery
Longer delays in surgery for ductal carcinoma in situ (DCIS) breast cancer lead to a higher risk of invasive ductal carcinoma and a slightly lower survival rate, researchers found. (Source: WebMD Health)
Source: WebMD Health - October 25, 2019 Category: Consumer Health News Source Type: news

Delay of Surgery for DCIS Ups Risk for Invasive Breast Cancer
FRIDAY, Oct. 25, 2019 -- For each month of delay between diagnosis and surgery for ductal carcinoma in situ (DCIS), there is slightly worse survival and an increase in risk for invasive disease, according to a study published online Sept. 27 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 25, 2019 Category: Pharmaceuticals Source Type: news

Sentinel lymph node biopsy unnecessary for DCIS
Performing sentinel lymph node biopsy in older women with ductal carcinoma...Read more on AuntMinnie.comRelated Reading: Chatbots boost women's understanding of breast biopsy Leica Biosystems unveils breast tissue biopsy container Biopsy rate is low after breast cancer 3D-printed breast biopsy device boosts accuracy Women overestimate breast cancer risk, prefer biopsy (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 25, 2019 Category: Radiology Source Type: news

Don't Delay Surgery for Very Early-Stage Breast Cancer, Study Suggests
THURSDAY, Oct. 24, 2019 -- Delaying surgery for a noninvasive breast cancer can have dire consequences, a new study shows. Longer delays in surgery for ductal carcinoma in situ (DCIS) breast cancer lead to a higher risk of invasive ductal carcinoma... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 24, 2019 Category: General Medicine Source Type: news

Nodular Hiradenoma, a Rare Mimic of Breast Carcinoma Nodular Hiradenoma, a Rare Mimic of Breast Carcinoma
This case report summarizes the clinical, pathological, and immunohistochemical characteristics of a breast hidradenoma, an uncommon skin adnexal tumor arising from the eccrine or apocrine glands.Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 14, 2019 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Mother, 47, diagnosed with skin cancer INSIDE her breast in 'rare phenomenon'
Michelle Miller, from Florida, was diagnosed with squamous cell carcinoma on the inside of her breast in May, and had both her breasts removed before giving birth to her daughter, Macy, in July. (Source: the Mail online | Health)
Source: the Mail online | Health - August 28, 2019 Category: Consumer Health News Source Type: news

Reverse signaling by semaphorin 4C elicits SMAD1/5- and ID1/3-dependent invasive reprogramming in cancer cells
Semaphorins are a family of molecular signals that guide cell migration and are implicated in the regulation of cancer cells. In particular, transmembrane semaphorins are postulated to act as both ligands ("forward" mode) and signaling receptors ("reverse" mode); however, reverse semaphorin signaling in cancer is relatively less understood. Here, we identified a previously unknown function of transmembrane semaphorin 4C (Sema4C), acting in reverse mode, to elicit nonconventional TGF-β/BMP receptor activation and selective SMAD1/5 phosphorylation. Sema4C coimmunoprecipitated with TGFBRII and BMPR1, ...
Source: Signal Transduction Knowledge Environment - August 20, 2019 Category: Science Authors: Gurrapu, S., Franzolin, G., Fard, D., Accardo, M., Medico, E., Sarotto, I., Sapino, A., Isella, C., Tamagnone, L. Tags: STKE Research Articles Source Type: news

AI Program May Aid in Pathologic Evaluation of Breast Biopsies
FRIDAY, Aug. 16, 2019 -- An artificial intelligence program outperforms pathologists for differentiating ductal carcinoma in situ (DCIS) from atypia, according to a study published online Aug. 9 in JAMA Network Open. Ezgi Mercan, Ph.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 16, 2019 Category: Pharmaceuticals Source Type: news

Artificial intelligence could yield more accurate breast cancer diagnoses
UCLA researchers have developed an artificial intelligence system that could help pathologists read biopsies more accurately and to better detect and diagnose breast cancer.The new system,described in a study published today in JAMA Network Open, helps interpret medical images used to diagnose breast cancer that can be difficult for the human eye to classify, and it does so nearly as accurately or better as experienced pathologists.“It is critical to get a correct diagnosis from the beginning so that we can guide patients to the most effective treatments,” said Dr. Joann Elmore, the study’s senior author ...
Source: UCLA Newsroom: Health Sciences - August 9, 2019 Category: Universities & Medical Training Source Type: news

Medical News Today: What to know about mucinous carcinoma
Mucinous carcinoma is a rare type of cancer that usually affects the breast. In this article, we look at its symptoms, causes, treatments, and the outlook. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 15, 2019 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Medical News Today: What to know about tubular carcinoma
Tubular carcinoma is a type of invasive breast cancer. In this article, learn more about the symptoms, causes, and treatment of tubular carcinoma and the outlook for people with this cancer. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 4, 2019 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Medical News Today: What to know about medullary breast carcinoma
Medullary breast carcinoma is a rare type of invasive breast cancer. In this article, we look at the symptoms, causes, and treatment of medullary breast carcinoma and the outlook for people with this cancer. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 4, 2019 Category: Consumer Health News Tags: Breast Cancer Source Type: news

FBS-Put it to Work
Priced RightWe provide, to our customers, the sameFetal Bovine Serum (FBS) we use in ourdefined media. This FBS enriched media is used in culturing all our human 2 and 3-D based Assays. Our FBS is of the highest quality and priced right at $379/500 ml.Here're some recent publications referencing its use.Gabriela Fernandes, Stephen T Vanyo, Shahad Bakheet Alsharif, Sebastiano Andreana, Michelle B Visser, Rosemary Dziak, Ph.D.Strontium Effects on Human Gingival Fibroblasts. https://doi.org/10.1563/aaid-joi-D-18-00253Douglas Dickinson, Shannon Xayaraj, Sarah Dickinson, Xueling Shao, and Stephen Hsu.  Effect of ...
Source: Neuromics - June 27, 2019 Category: Neuroscience Tags: 3-D Cell based Assays Cell Cultures FBS Fetal Bovine Serum Source Type: news

Contrast ultrasound can tell DCIS from fibroadenomas
Contrast-enhanced ultrasound can distinguish ductal carcinoma in situ (DCIS)...Read more on AuntMinnie.comRelated Reading: Ultrasound options abound for diagnosing liver disease ICUS applauds payment changes for CEUS Contrast ultrasound helps characterize breast lesions Drop ultrasound contrast agent warning, society says Contrast US tops CT, MRI for classifying kidney tumors (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 19, 2019 Category: Radiology Source Type: news

Dr. Meyers on Low-Dose Tamoxifen vs Placebo After Surgery for DCIS Breast Cancer
Cancer Network spoke with Marleen Meyers, MD, about evidence on  low-dose tamoxifen vs placebo in women who had surgery for their ductal carcinoma in situ. (Source: CancerNetwork)
Source: CancerNetwork - June 17, 2019 Category: Cancer & Oncology Authors: Marleen Meyers, MD Source Type: news